An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy

Uesugi, Yoshiko; Kawata, Hiroyuki; Jo, Jun-ichiro; Saito, Yoshihiko; Tabata, Yasuhiko

doi:10.1016/j.jconrel.2010.07.127

Cited by 100 publications

(73 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cationized GNPs can be used for complexion with anionic drugs rather than nucleic acids. Ethylenediamine gelatin nanoparticles electrostatically interact with anionic tissue-type plasminogen activators (t-PA) to form nano-sized t-PA-gelatin delivery complex [113]. The thrombolytic activity of t-PA-gelatin complex is significantly suppressed to 45% of original t-PA but when exposed to ultrasound in vitro, its activity is fully recovered.…”

Section: Cationized Gnpsmentioning

confidence: 99%

Recent advancement of gelatin nanoparticles in drug and vaccine delivery

Sahoo

Biswas

et al. 2015

International Journal of Biological Macromolecules

229

100

View full text Add to dashboard Cite

Section: Cationized Gnpsmentioning

confidence: 99%

Recent advancement of gelatin nanoparticles in drug and vaccine delivery

Sahoo

Biswas

et al. 2015

International Journal of Biological Macromolecules

229

100

View full text Add to dashboard Cite

“…Since then, US has been established as an effective external trigger for enhanced drug delivery by acoustically agitating vesicles containing encapsulated gas. Several vascular drug delivery vehicles have been proposed to encapsulate therapeutics, such as nanogels [102,103], micelles [104,105] and perfluorocarbon droplet emulsions [106][107][108]. Drugs and bioactive gases have also been encapsulated in nanometer and micron-sized echogenic liposomes [109][110][111][112][113][114].…”

Section: Vehicles For Enhanced Drug Deliverymentioning

confidence: 99%

Ultrasound-Mediated Drug Delivery for Cardiovascular Disease

Holland

2017

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

Introduction-Ultrasound (US) has been developed as both a valuable diagnostic tool and a potent promoter of beneficial tissue bioeffects for the treatment of cardiovascular disease. These effects can be mediated by mechanical oscillations of circulating microbubbles, or US contrast agents, which may also encapsulate and shield a therapeutic agent in the bloodstream. Oscillating microbubbles can create stresses directly on nearby tissue or induce fluid effects that effect drug penetration into vascular tissue, lyse thrombi or direct drugs to optimal locations for delivery.Areas covered-The present review summarizes investigations that have provided evidence for US-mediated drug delivery as a potent method to deliver therapeutics to diseased tissue for cardiovascular treatment. In particular, the focus will be on investigations of specific aspects relating to US-mediated drug delivery, such as delivery vehicles, drug transport routes, biochemical mechanisms and molecular targeting strategies.Expert opinion-These investigations have spurred continued research into alternative therapeutic applications, such as bioactive gas delivery and new US technologies. Successful implementation of US-mediated drug delivery has the potential to change the way many drugs are administered systemically, resulting in more effective and economical therapeutics, and lessinvasive treatments.

show abstract

“…PEG-gelatin nanocarriers also prolonged the circulation of tPA and released it in an ultrasound-responsive fashion, improving recanalization of occlusive clots in rabbits. 29 Further refinements of the ELIP approach are warranted, as potent ultrasound may inactivate PAs 30 and cause vascular damage. Some clots may not be amenable to this approach due to unknown location or risk of hemorrhage.…”

Section: Ata Carriers Sensitive To Ultrasound and Hydrodynamic Forcesmentioning

confidence: 99%

Advanced drug delivery systems for antithrombotic agents

Greineder

Howard

Carnemolla

et al. 2013

Blood

View full text Add to dashboard Cite

Despite continued achievements in antithrombotic pharmacotherapy, difficulties remain in managing patients at high risk for both thrombosis and hemorrhage. Utility of antithrombotic agents (ATAs) in these settings is restricted by inadequate pharmacokinetics and narrow therapeutic indices. Use of advanced drug delivery systems (ADDSs) may help to circumvent these problems. Various nanocarriers, affinity ligands, and polymer coatings provide ADDSs that have the potential to help optimize ATA pharmacokinetics, target drug delivery to sites of thrombosis, and sense pathologic changes in the vascular microenvironment, such as altered hemodynamic forces, expression of inflammatory markers, and structural differences between mature hemostatic and growing pathological clots. Delivery of ATAs using biomimetic synthetic carriers, host blood cells, and recombinant fusion proteins that are activated preferentially at sites of thrombus development has shown promising outcomes in preclinical models. Further development and translation of ADDSs that spare hemostatic fibrin clots hold promise for extending the utility of ATAs in the management of acute thrombotic disorders through rapid, transient, and targeted thromboprophylaxis. If the potential benefit of this technology is to be realized, a systematic and concerted effort is required to develop clinical trials and translate the use of ADDSs to the clinical arena.

show abstract

An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy

Cited by 100 publications

References 76 publications

Recent advancement of gelatin nanoparticles in drug and vaccine delivery

Recent advancement of gelatin nanoparticles in drug and vaccine delivery

Ultrasound-Mediated Drug Delivery for Cardiovascular Disease

Advanced drug delivery systems for antithrombotic agents

Contact Info

Product

Resources

About